conjugate of plasmid dna with linear polyethylenimine 20 kda (pei)
Vaccineexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 28, 2001 (NCT00988767)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06631092 | Phase 1/Phase 2 (Phase 2) | Oct 15, 2024 | NEC |
| NCT05799144 | Phase 2 | May 16, 2023 | Vanderbilt University |
| NCT04049864 | Early Phase 1 (Phase 1) | Jan 9, 2019 | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology |
| NCT00988767 | Phase 1 | Feb 28, 2001 | Institut National de la Santé Et de la Recherche Médicale, France, University of Paris |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Institut National de la Santé Et de la Recherche Médicale, France | Academic/Hospital | 1 | 1 | 1 | 2001 |
| NEC | For profit | 1 | 1 | 1 | 2024 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2001 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1